Two eligibility periods are presented due to the COVID-19 pandemic: 4 September 2020 is the date the trial officially closed to recruitment, and 23 March 2020 was the start of the UK national lockdown. No participants were recruited between 23 March 2020 and 4 September 2020. Two participants did not have a cold ischemic time (CIT) reported, and two participants received dual transplants and, hence, do not have a left/right kidney variable populated; these four cases were excluded from all risk-adjusted modeling. Two additional exclusion criteria (donors who underwent normothermic regional perfusion or one of a pair already randomized as a single kidney in the trial) were introduced on 13 October 2017, and, retrospectively, two participants fulfilled these exclusion criteria (both were randomized to NMP). These patients were included in the MITT analysis and excluded from the per-protocol analysis.
